GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » Piotroski F-Score

BioLife Solutions (BioLife Solutions) Piotroski F-Score : 5 (As of May. 03, 2024)


View and export this data going back to 1992. Start your Free Trial

What is BioLife Solutions Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BioLife Solutions has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for BioLife Solutions's Piotroski F-Score or its related term are showing as below:

BLFS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of BioLife Solutions was 7. The lowest was 2. And the median was 4.


BioLife Solutions Piotroski F-Score Historical Data

The historical data trend for BioLife Solutions's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Piotroski F-Score Chart

BioLife Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 2.00 4.00 5.00

BioLife Solutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 2.00 4.00 3.00 5.00

Competitive Comparison of BioLife Solutions's Piotroski F-Score

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -13.714 + -10.199 + -29.132 + -13.382 = $-66.4 Mil.
Cash Flow from Operations was -2.712 + -7.718 + -4.379 + 2.311 = $-12.5 Mil.
Revenue was 37.703 + 39.508 + 33.328 + 32.733 = $143.3 Mil.
Gross Profit was 14.039 + 11.812 + 11.649 + 9.25 = $46.8 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(450.229 + 446.47 + 433.177 + 411.152 + 412.714) / 5 = $430.7484 Mil.
Total Assets at the begining of this year (Dec22) was $450.2 Mil.
Long-Term Debt & Capital Lease Obligation was $32.7 Mil.
Total Current Assets was $120.6 Mil.
Total Current Liabilities was $42.2 Mil.
Net Income was -7.421 + -72.878 + -10.317 + -49.189 = $-139.8 Mil.

Revenue was 36.22 + 40.533 + 40.747 + 44.259 = $161.8 Mil.
Gross Profit was 11.774 + 14.339 + 13.738 + 13.971 = $53.8 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(554.286 + 544.012 + 470.379 + 487.679 + 450.229) / 5 = $501.317 Mil.
Total Assets at the begining of last year (Dec21) was $554.3 Mil.
Long-Term Debt & Capital Lease Obligation was $38.9 Mil.
Total Current Assets was $138.5 Mil.
Total Current Liabilities was $44.6 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BioLife Solutions's current Net Income (TTM) was -66.4. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BioLife Solutions's current Cash Flow from Operations (TTM) was -12.5. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-66.427/450.229
=-0.14754047

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-139.805/554.286
=-0.25222539

BioLife Solutions's return on assets of this year was -0.14754047. BioLife Solutions's return on assets of last year was -0.25222539. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

BioLife Solutions's current Net Income (TTM) was -66.4. BioLife Solutions's current Cash Flow from Operations (TTM) was -12.5. ==> -12.5 > -66.4 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=32.685/430.7484
=0.07587956

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=38.881/501.317
=0.07755771

BioLife Solutions's gearing of this year was 0.07587956. BioLife Solutions's gearing of last year was 0.07755771. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=120.604/42.178
=2.85940538

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=138.452/44.582
=3.1055583

BioLife Solutions's current ratio of this year was 2.85940538. BioLife Solutions's current ratio of last year was 3.1055583. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

BioLife Solutions's number of shares in issue this year was 44.832. BioLife Solutions's number of shares in issue last year was 47.748. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=46.75/143.272
=0.32630242

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=53.822/161.759
=0.33272955

BioLife Solutions's gross margin of this year was 0.32630242. BioLife Solutions's gross margin of last year was 0.33272955. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=143.272/450.229
=0.31822028

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=161.759/554.286
=0.2918331

BioLife Solutions's asset turnover of this year was 0.31822028. BioLife Solutions's asset turnover of last year was 0.2918331. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+1+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BioLife Solutions has an F-score of 5 indicating the company's financial situation is typical for a stable company.

BioLife Solutions  (NAS:BLFS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


BioLife Solutions Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLife Solutions (BioLife Solutions) Business Description

Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
Executives
Geraint Phillips officer: SVP, Global Operations 3303 MONTE VILLA, #310, BOTHELL WA 98021
Sarah Aebersold officer: VP, Global Human Resources BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman officer: Chief Financial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Greef Roderick De director
Aby J. Mathew officer: Chief Tech. Officer & Sr. VP 3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard officer: Vice President, Marketing 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster officer: Vice President of Operations C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Michael Rice director, officer: President & CEO C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Garrie Richardson officer: Chief Revenue Officer 3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Marcus Schulz officer: Vice President, Global Sales 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick director 16719 NE 139TH PLACE, WOODINVILLE WA 98072
Amy Duross director 8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami director SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023